玻璃体内无防腐剂型曲安奈德治疗黄斑水肿  

Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema

作　　者：Bakri S.J. Shah A. Falk N.S. Beer P.M. 杜兆江 

机构地区：[1]Cole Eye Institute, i-20 Cleveland Clinic Foundation, Cleveland, OH 44195, United States

出　　处：《世界核心医学期刊文摘（眼科学分册）》2005年第10期32-33,共2页Digest of the World Core Medical Journals:Ophthalmology

摘　　要：Purpose: To report the use of commercially available preservative-free intrav itreal triamcinolone acetonide for the treatment of macular oedema due to retina l vascular diseases. Design: Retrospective interventional case series. Methods: Charts of eyes that received 4 mg preservative-free intravitreal triamcinolone acetonide for the treatment of persistent macular oedema due to retinal vascular diseases were reviewed. Patients were included if they had a follow-up of at least 3 months. Visual acuity, intraocular pressure, presence of an anterior cha mber reaction, and mean macular thickness on optical coherence tomography (OCT) were recorded. Results: A total of 10 eyes of 10 patients were identified. Visua l acuity improved by a mean of 1.1 Suellen lines at 1 month and 1.3 lines at 3 m onths. Macular thickness on OCT decreased by a mean of 183.5 μm at 1 month (P< 0.0001). Intraocular pressure increased from a mean of 13.5 mmHg at baseline to 15.3 at 1 month, and 14.5 at 3 months. Only the 1-month change in intraocular p ressure was statistically significant (P=0.0274). There were no cases of endopht halmitis, anterior chamber reaction, or retinal detachment. Conclusion: In this small retrospective, noncomparative series, commercially available preservative -free intravitreal triamcinolone acetonide had no adverse outcomes. Macular oed ema was noted to decrease following treatment.Purpose: To report the use of commercially available preservative-free intrav itreal triamcinolone acetonide for the treatment of macular oedema due to retina l vascular diseases. Design: Retrospective interventional case series. Methods: Charts of eyes that received 4 mg preservative-free intravitreal triamcinolone acetonide for the treatment of persistent macular oedema due to retinal vascular diseases were reviewed. Patients were included if they had a follow-up of at least 3 months. Visual acuity, intraocular pressure, presence of an anterior cha mber reaction, and mean macular thickness on optical coherence tomography (OCT) were recorded. Results: A total of 10 eyes of 10 patients were identified. Visua l acuity improved by a mean of 1.1 Suellen lines at 1 month and 1.3 lines at 3 m onths. Macular thickness on OCT decreased by a mean of 183.5 μm at 1 month (P< 0.0001). Intraocular pressure increased from a mean of 13.5 mmHg at baseline to 15.3 at 1 month, and 14.5 at 3 months. Only the 1-month change in intraocular p ressure was statistically significant (P=0.0274). There were no cases of endopht halmitis, anterior chamber reaction, or retinal detachment. Conclusion: In this small retrospective, noncomparative series, commercially available preservative -free intravitreal triamcinolone acetonide had no adverse outcomes. Macular oed ema was noted to decrease following treatment.

关 键 词：黄斑水肿 视网膜血管 前房反应 视网膜脱离 眼内炎 眼图 

分 类 号：R774.5[医药卫生—眼科]